This page shows the latest inherited retinal disease news and features for those working in and with pharma, biotech and healthcare.
ALS community, and we welcome this important research advancement in this difficult to treat disease space.”. ... retinitis pigmentosa, a rare, inherited retinal disease that is associated with progressive vision loss, in May.
Specifically, the complaint accuses bluebird bio of infringing on and diluting Spark Therapeutics’ trademark, relating to bluebird bio’s educational and informational campaign about sickle cell disease ‘Be the Spark’ which ... The biotech company
neparvovec) for a rare inherited retinal disease – as well as four other candidates in clinical trials headed by haemophilia A therapy SPK-8011.
The $114.50 per share deal will give the Swiss pharma giant rights the approved therapy Luxturna (voretigene neparvovec) for a rare inherited retinal disease, as well as four candidates in ... Also in Spark’s pipeline is SPK-7001 for choroideremia in
The companies will also work together on new targets for other inherited retinal diseases and on adeno-associated virus (AAV) manufacturing technology. ... The US market developed a little later, with Spark Therapeutics’ Luxturna (voretigene neparvovec
additional testing of its lead haemophilia B gene therapy, and take another for Fabry disease into the clinic. ... This adds to Freeline and its focus on chronic systemic disease, Nightstar ( specialising in inherited retinal diseases), and Gyroscope,
More from news
Approximately 3 fully matching, plus 7 partially matching documents found.
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...